Joint 10th AGCST and ASSCR Scientific Meeting, Sydney
25 MAY 2017Presentations and Publications
Read about publications and presentations made by Benitec's scientific team below. For details of Benitec's announcements to NASDAQ, read details in our Investor Centre.2017
Towards Development of a ‘Silence and Replace’ Based Approach for the Treatment of Oculopharyngeal Muscular Dystrophy.
Significant Enhancement of Hepatitis B Virus (HBV) Suppression with Standard of Care Drugs Following Co-Administration of a DNA-Directed RNA Interference Agent in a Chimeric Mouse Model
Joint 10th AGCST and ASSCR Scientific Meeting, Sydney
24 MAY 2017
Superior suppression of Hepatitis B virus (HBV) DNA and antigen levels in a chimeric mouse model when BB-103, a DNA-Directed RNA interference (ddRNAi) agent, is coupled with standard of care drugs
EASL, The International Liver Conference 2017, Amsterdam
19 APR 2017
Combinations of a DNA-Directed RNA Interference Agent With Standard of Care Drugs Results in Superior Suppression of Hepatitis B Virus (HBV) in a Chimeric Mouse Model
EASL, The International Liver Conference 2017, Amsterdam
19 FEB 2017
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
Nat. Commun. 8, 14848 doi: 10.1038/ ncomms14848 (2017)
1 JAN 20172016
BB-HB-331, a DNA-Directed RNA Interference Agent, Suppresses Hepatitis B virus (HBV) in vitro and in vivo
European Society of Gene and Cell Therapy (ESGCT) 2016 Annual Congress, Florence
18 OCT 2016
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
A comparison of scAAV8-TT034 mediated transduction and shRNA expression in human liver biopsy samples versus a chimeric mouse model with humanized liver
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016
Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV)
ASGCT 19th Annual Meeting, Washington DC
5 MAY 2016